On April 10th, Kangtai Biological said that the pre-printed version of the phase I/II clinical trial data of the inactivated new crown vaccine independently developed by the company showed the superiority, safety and immunogenicity of its products.
The neutralizing antibody GMT (IU/ml) of live virus was 131.
7, which was 2.
65 times that of the recovered serum neutralizing antibody GMT 49.
The clinical data of the new crown vaccine compiled by the medical team of Dongxing Securities shows that the antibody titer vaccine group/recovered multiple of them ranks first in China and fourth in the world.
(Associated Finance Press/ Ding Rong )